Patents Assigned to Pfizer
  • TREATMENT WITH ANTI-EFNA4 ANTIBODY-DRUG CONJUGATES
    Publication number: 20180099054
    Abstract: The present invention provides for dosing regimens for the treatment of patients with cancer and/or an EFNA4-associated disorder with an anti-EFNA4 antibody-drug conjugate (ADC). The present invention further provides for methods for the treatment of patients with cancer and/or an EFNA4-associated disorder in which an anti-EFNA4 ADC is administered intravenously weekly (QW) or every 3 weeks (Q3W).
    Type: Application
    Filed: May 12, 2016
    Publication date: April 12, 2018
    Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: ASHWIN GOLLERKERI, KAREN VELASTEGUI, RAFFAELE BAFFA, JAYMES SCOT HOLLAND
  • Tofacitinib oral sustained release dosage forms
    Patent number: 9937181
    Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: April 10, 2018
    Assignee: Pfizer Inc.
    Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
  • ANTI-PTK7 ANTIBODY-DRUG CONJUGATES
    Publication number: 20180094075
    Abstract: The present invention provides anti-PTK7 antibody-drug conjugates and methods for preparing and using the same.
    Type: Application
    Filed: September 1, 2017
    Publication date: April 5, 2018
    Applicants: PFIZER INC., ABBVIE STEMCENTRX LLC
    Inventors: Marc Isaac DAMELIN, Puja SAPRA, Alexander John BANKOVICH, Scott J. DYLLA
  • Process for annealing amorphous atorvastatin
    Patent number: 9932307
    Abstract: Processes for annealing amorphous atorvastatin is described. Pharmaceutical compositions and formulations containing annealed amorphous atorvastatin are also described.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: April 3, 2018
    Assignee: Pfizer Inc.
    Inventors: Renuka Devi Reddy, Evgenyi Shalaev, Ravi Mysore Shanker, Carl Bernard Ziegler
  • CRYSTALLINE FORMS OF 1-((2R,4R)-2-(1H-BENZO[D]IMIDAZOL-2-YL)-1-METHYLPIPERIDIN-4-YL)-3-(4-CYANOPHENYL)UREA MALEATE
    Publication number: 20180086731
    Abstract: This invention relates to a crystalline form of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 29, 2018
    Applicant: PFIZER INC.
    Inventors: Eric Christian Hansen, Christopher Scott Seadeek
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20180086736
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: December 7, 2017
    Publication date: March 29, 2018
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Patent number: 9920054
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 20, 2018
    Assignee: Pfizer Inc.
    Inventor: Mark Edward Schnute
  • Crystalline form of 6-[(4R)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]iosoquinoline-1-carbonitrile
    Patent number: 9920043
    Abstract: This invention relates to a novel crystalline form of 6-[(4R)-4-methyl-1,1-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile which is useful as a selective androgen receptor modulator (SARM), and to compositions thereof and suitable processes for the preparation thereof.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: March 20, 2018
    Assignee: Pfizer Inc.
    Inventors: Eugene Lvovich Piatnitski Chekler, Roberta Louise Dorow, Jeffrey Braden Sperry
  • HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS
    Publication number: 20180072750
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.
    Type: Application
    Filed: November 27, 2017
    Publication date: March 15, 2018
    Applicant: PFIZER INC.
    Inventors: DAVID LAWRENCE FIRMAN GRAY, LEI ZHANG, JENNIFER ELIZABETH DAVOREN, AMY BETH DOUNAY, IVAN VIKTOROVICH EFREMOV, CHEWAH LEE, SCOT RICHARD MENTE, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, CHAKRAPANI SUBRAMANYAM
  • SOLID FORMS OF A SELECTIVE CDK4/6 INHIBITOR
    Publication number: 20180065964
    Abstract: This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicant: PFIZER INC.
    Inventors: Brian Patrick Chekal, Nathan D. Ide
  • 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS
    Publication number: 20180065943
    Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.
    Type: Application
    Filed: November 9, 2017
    Publication date: March 8, 2018
    Applicant: PFIZER INC.
    Inventors: CHRISTOPHER RYAN BUTLER, LAURA ANN MCALLISTER, ELIZABETH MARY BECK, MICHAEL AARON BRODNEY, ADAM MATTHEW GILBERT, CHRISTOPHER JOHN HELAL, DOUGLAS SCOTT JOHNSON, JUSTIN IAN MONTGOMERY, STEVEN VICTOR O'NEIL, BRUCE NELSEN ROGERS, PATRICK ROBERT VERHOEST, DAMIEN WEBB
  • Salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatonic acid
    Patent number: 9908850
    Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Joseph Francis Krzyzaniak, Jason Albert Leonard
  • N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors
    Patent number: 9908883
    Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: March 6, 2018
    Assignee: Pfizer Inc.
    Inventors: Mary Didiuk, Robert Lee Dow, David Andrew Griffith
  • BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR
    Publication number: 20180057600
    Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Application
    Filed: November 8, 2017
    Publication date: March 1, 2018
    Applicants: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Jing MIN, Yanli Wu, Rory F. Finn, Barrett R. Thiele, Wei Liao, Ronald P. Gladue, Arvind Rajpal, Timothy J. Paradis, Peter Brams, Brigitte Devaux, Yi Wu, Kristopher Toy, Heidi N. Leblanc, Haichun Huang
  • Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer
    Publication number: 20180055926
    Abstract: A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. The present invention is further directed to pharmaceutical compositions for treatment of cancer. The intralesional chemoablative pharmaceutical composition can comprise an IL chemoablative agent comprising primarily a halogenated xanthene.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Applicants: Provectus Pharmatech, Inc., Pfizer, Inc.
    Inventors: Craig J. EAGLE, H. Craig DEES, Eric A. WACHTER, Jamie SINGER
  • Intermediates and methods for synthesizing calicheamicin derivatives
    Patent number: 9902691
    Abstract: The present invention relates to intermediates of Formula I and to methods of synthesizing and purifying calicheamicin derivatives.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: February 27, 2018
    Assignee: Pfizer Inc.
    Inventors: Robert Wayne Dugger, Leo Joseph Letendre, Vimalkumar Babubhai Patel, Amarnauth Shastrie Prashad, Chunchun Zhang
  • DIACYLGLYCEROL ACYL TRANSFERASE 2 INHIBITORS
    Publication number: 20180051012
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: August 11, 2017
    Publication date: February 22, 2018
    Applicant: Pfizer Inc.
    Inventors: Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
  • Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same
    Patent number: 9895378
    Abstract: The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 20, 2018
    Assignee: Pfizer Inc.
    Inventors: Shubha Bagrodia, Jennifer Lafontaine, Zach Lovatt, Eyoung Shin, Young Ho Song, Greg Troiano, Hong Wang
  • DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS
    Publication number: 20180042926
    Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
    Type: Application
    Filed: September 1, 2017
    Publication date: February 15, 2018
    Applicant: Pfizer Inc.
    Inventor: Kentaro Futatsugi
  • CDK2/4/6 Inhibitors
    Publication number: 20180044344
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 15, 2018
    Applicant: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui